Author: Kam, Yiu Wing; Kien, François; Roberts, Anjeanette; Cheung, Yan Chung; Lamirande, Elaine W.; Vogel, Leatrice; Chu, Shui Ling; Tse, Jane; Guarner, Jeannette; Zaki, Sherif R.; Subbarao, Kanta; Peiris, Malik; Nal, Béatrice; Altmeyer, Ralf
Title: Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro Cord-id: mqnz9gts Document date: 2007_1_8
ID: mqnz9gts
Snippet: Vaccine-induced antibodies can prevent or, in the case of feline infectious peritonitis virus, aggravate infections by coronaviruses. We investigated whether a recombinant native full-length S-protein trimer (triSpike) of severe acute respiratory syndrome coronavirus (SARS-CoV) was able to elicit a neutralizing and protective immune response in animals and analyzed the capacity of anti-S antibodies to mediate antibody-dependent enhancement (ADE) of virus entry in vitro and enhancement of replica
Document: Vaccine-induced antibodies can prevent or, in the case of feline infectious peritonitis virus, aggravate infections by coronaviruses. We investigated whether a recombinant native full-length S-protein trimer (triSpike) of severe acute respiratory syndrome coronavirus (SARS-CoV) was able to elicit a neutralizing and protective immune response in animals and analyzed the capacity of anti-S antibodies to mediate antibody-dependent enhancement (ADE) of virus entry in vitro and enhancement of replication in vivo. SARS-CoV-specific serum and mucosal immunoglobulins were readily detected in immunized animals. Serum IgG blocked binding of the S-protein to the ACE2 receptor and neutralized SARS-CoV infection in vitro. Entry into human B cell lines occurred in a FcγRII-dependent and ACE2-independent fashion indicating that ADE of virus entry is a novel cell entry mechanism of SARS-CoV. Vaccinated animals showed no signs of enhanced lung pathology or hepatitis and viral load was undetectable or greatly reduced in lungs following challenge with SARS-CoV. Altogether our results indicate that a recombinant trimeric S protein was able to elicit an efficacious protective immune response in vivo and warrant concern in the safety evaluation of a human vaccine against SARS-CoV.
Search related documents:
Co phrase search for related documents- acute sars cov respiratory syndrome coronavirus and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute sars cov respiratory syndrome coronavirus and adjuvant alum: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute sars cov respiratory syndrome coronavirus and adjuvant immunization: 1, 2, 3, 4
- acute sars cov respiratory syndrome coronavirus and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute sars cov respiratory syndrome coronavirus and liver enzyme level: 1, 2
- acute sars cov respiratory syndrome coronavirus and low dose receive: 1, 2
- acute sars cov respiratory syndrome coronavirus and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute sars cov respiratory syndrome coronavirus and luciferase reporter gene: 1, 2, 3, 4, 5, 6
- acute sars cov respiratory syndrome coronavirus and lung challenge: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute sars cov respiratory syndrome coronavirus and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- acute sars cov respiratory syndrome coronavirus and lysis buffer: 1, 2, 3
- acute sars cov respiratory syndrome coronavirus and mab monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute sars cov respiratory syndrome coronavirus and macrophage cell line: 1, 2
- additional hamster and lung pathology: 1
Co phrase search for related documents, hyperlinks ordered by date